PNAS:研究发现利尿剂新的治疗基因靶标

2012-08-01 范振光 生物谷

  近日,辛辛那提大学(UC)研究人员已经确定了利尿剂治疗那些如充血性心脏衰竭、肝硬化或肾功能衰竭患者新的治疗靶标。 这些结果发表在7月30日的PNAS期刊上,这可能会导致25年来第一个新的利尿剂治疗可以帮助利尿剂抵抗的患者。     Manoocher Soleimani医师说利尿剂的作用是增加尿量帮助患者处理自己多余的液体,因为他们的肾脏是无法做到的。在过去的几十年中,医生已使用

  近日,辛辛那提大学(UC)研究人员已经确定了利尿剂治疗那些如充血性心脏衰竭、肝硬化或肾功能衰竭患者新的治疗靶标。 这些结果发表在7月30日的PNAS期刊上,这可能会导致25年来第一个新的利尿剂治疗可以帮助利尿剂抵抗的患者。
 
  Manoocher Soleimani医师说利尿剂的作用是增加尿量帮助患者处理自己多余的液体,因为他们的肾脏是无法做到的。在过去的几十年中,医生已使用利尿剂,单独用或组合用以帮助水潴留病人,他说水潴留病人可能会发生心脏​​衰竭、肾功能衰竭或其他严重疾病症状。
 
  全世界最常使用的是利尿嗪,它能抑制肾脏的保水能力,同时这些药物也可以用来降低血压,它们如此广泛使用的原因是因为它们药性温和,不会引起严重机体液体亏损。然而,这些药物并不是对每一位病人都有效,在这项研究中,研究人员检查了肾脏中称为肾小管的特定部分以及位于促部位发挥吸收盐分功能的基因。
 
  Soleimani说:盐或钠氯化物也即共同转运体(NCC)是氢氯噻嗪这一类的药物的治疗靶点,它类似于吸收氯的转运体潘特林,这两者都在肾脏中吸收盐分。当潘特林从身体中去除后,对盐排泄没有影响。我们认为潘特林能以某种方式帮助共同转运体(NCC),所以利用基因敲除动物模型发现这两个基因相互弥补彼此,如果NCC无法正常工作,那么潘特林会代替其发挥作用。
 
  Soleimani说,这些结果可能会导致有针对性的利尿治疗方法的产生,抑制潘特林可以进一步帮助治疗液体超负荷严重的患者。 研究人员表示:给予患者一种潘特林抑制剂与轻度利尿剂噻嗪类可以大大减轻体液潴留,这种治疗选择能提高患者的治疗效果。

Double knockout of pendrin and Na-Cl cotransporter (NCC) causes severe salt wasting, volume depletion, and renal failure

Manoocher Soleimania,Sharon Baronea,b,c, Jie Xua,b,c, Gary E. Shulld, Faraz Siddiquib, Kamyar Zahedia,b,c, and Hassane Amlalb,c

The Na-Cl cotransporter (NCC), which is the target of inhibition by thiazides, is located in close proximity to the chloride-absorbing transporter pendrin in the kidney distal nephron. Single deletion of pendrin or NCC does not cause salt wasting or excessive diuresis under basal conditions, raising the possibility that these transporters are predominantly active during salt depletion or in response to excess aldosterone. We hypothesized that pendrin and NCC compensate for loss of function of the other under basal conditions, thereby masking the role that each plays in salt absorption. To test our hypothesis, we generated pendrin/NCC double knockout (KO) mice by crossing pendrin KO mice with NCC KO mice. Pendrin/NCC double KO mice displayed severe salt wasting and sharp increase in urine output under basal conditions. As a result, animals developed profound volume depletion, renal failure, and metabolic alkalosis without hypokalemia, which were all corrected with salt replacement. We propose that the combined inhibition of pendrin and NCC can provide a strong diuretic regimen without causing hypokalemia for patients with fluid overload, including patients with congestive heart failure, nephrotic syndrome, diuretic resistance, or generalized edema.

 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1752975, encodeId=78291e5297519, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Nov 01 09:20:00 CST 2012, time=2012-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855308, encodeId=dfed185530802, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Mar 18 06:20:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271916, encodeId=735c12e1916e5, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Fri Aug 03 02:20:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352705, encodeId=2f241352e051e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 03 02:20:00 CST 2012, time=2012-08-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1752975, encodeId=78291e5297519, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Nov 01 09:20:00 CST 2012, time=2012-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855308, encodeId=dfed185530802, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Mar 18 06:20:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271916, encodeId=735c12e1916e5, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Fri Aug 03 02:20:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352705, encodeId=2f241352e051e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 03 02:20:00 CST 2012, time=2012-08-03, status=1, ipAttribution=)]
    2013-03-18 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=1752975, encodeId=78291e5297519, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Nov 01 09:20:00 CST 2012, time=2012-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855308, encodeId=dfed185530802, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Mar 18 06:20:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271916, encodeId=735c12e1916e5, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Fri Aug 03 02:20:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352705, encodeId=2f241352e051e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 03 02:20:00 CST 2012, time=2012-08-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1752975, encodeId=78291e5297519, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Thu Nov 01 09:20:00 CST 2012, time=2012-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855308, encodeId=dfed185530802, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Mar 18 06:20:00 CST 2013, time=2013-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271916, encodeId=735c12e1916e5, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Fri Aug 03 02:20:00 CST 2012, time=2012-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352705, encodeId=2f241352e051e, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Fri Aug 03 02:20:00 CST 2012, time=2012-08-03, status=1, ipAttribution=)]
    2012-08-03 zhaojie88

相关资讯

噻嗪类利尿剂存在显著效力差异

  英国学者的一项荟萃分析表明,氢氯噻嗪、氯噻酮和苄氟噻嗪在效力方面存在显著差异,这可能解释了标准剂量氢氯噻嗪和氯噻酮的降压效果差异。论文于2012年4月30日在线发表于《高血压》(Hypertension)杂志。   噻嗪类和噻嗪样利尿剂被广泛用于高血压治疗,但近来对氢氯噻嗪和氯噻酮在降压和心血管疾病预防方面的等效性有所质疑。此项研究对3种广泛应用噻嗪类利尿剂(氢氯噻嗪、氯噻酮和苄氟噻嗪)与血